Answers are grounded in this paper and cite their sources.
The degradation of atrazine [2-chloro-4-(ethylamino)-6-isopropylamino-1,3,5-triazine], deethylatrazine [DEA; 2-amino-4-chloro-6-(isopropylamino)-1,3,5-triazine], and deisopropylatrazine [DIA; 2-amino-4-chloro-6-(ethylamino)-1,3,5-triazine] was assessed under limited oxygen conditions using in situ microcosms. Denitrification was induced in a shallow sand and gravel aquifer to measure the potential for degradation of atrazine, DEA, and DIA under low-O(2) conditions. The dissolved oxygen content decreased from 7-8 mg/L to </=1 mg/L within 4 days and remained less, similar3 mg/L for the remainder of the 45-day experiment. Atrazine, DEA, and DIA concentrations (normalized to the bromide concentration at each sampling time to account for dilution) did not show a significant decrease with time, indicating that these compounds are relatively stable under the low-O(2) conditions induced in the aquifer. Although removal of one alkyl group has been proposed as the rate-limiting step in atrazine degradation, no transformation of either monodealkylated metabolite (DEA or DIA) was observed in this study.
No takes yet. Share an insight, caveat, or question.
Papiernik et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: